- Description
- Inquiry
Description
Simple description
Products name: Cetilistat
Cetilistat is a new gastrointestinal lipase inhibitor, which was developed by Alizyme in the UK. Later, “Norgina BV” won the global agency of “Cetilistat”. In Japan, due to cooperation with Takeda Pharmaceuticals, Xinlishitar was approved as a drug for treating obesity in September 2013. The product name is “Oblian”. Neolistat is a long-term and powerful specific gastrointestinal lipase inhibitor. It plays a therapeutic role by forming a Covalent bond with the active serine site of gastric lipase and pancreatic lipase in the stomach and small intestine cavity to inactivate the enzyme. Inactive enzymes cannot hydrolyze the fat in food, mainly triglycerides, into absorbable free fatty acids and monoacylglycerols, and undigested triglycerides cannot be absorbed by the body, To reduce calorie intake and control weight.
Chinese name: Xinlishitar
Chinese alias: 2-hexadecyl oxy-6-methyl-4H-3,1-benzoxazine-4-one
English name: Cetilistat
English alias: 2- (Hexadecycloxy) -6-methyl-4H-3,1-benzoxazin-4-one; Cetilstat; 2-Hexadecycloxy-6-methyl-4H-3,1-benzoxazin-4-one;
CAS number: 282526-98-1
Molecular formula: C25H39NO3
Molecular weight: 401.58200
Precision quality: 401.29300
PSA: 52.33000
LogP: 7.35650
Physical and chemical properties
Appearance and properties: White or almost white powder
Density: 1.027g/cm3
Boiling point: 509.671? C at 760 mmHg
Flash point: 158.925? C
Refractive index: 1.521
Steam pressure: 0mmHg at 25 ° C
